Sequencing the head and neck cancer genome: Implications for therapy

Annals of the New York Academy of Sciences

Volumn 1333, Issue 1, 2014, Pages 33-42

  Sun, Wenyue ^a   Califano, Joseph A ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b GREATER BALTIMORE MEDICAL CENTER   (United States)

Author keywords

Head and neck cancer; Mutation; Next generation sequencing; NOTCH1

Indexed keywords

HUMAN PAPILLOMAVIRUS; NICOTIANA TABACUM;

ANIMAL; CARCINOMA, SQUAMOUS CELL; GENETICS; HEAD AND NECK NEOPLASMS; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN GENOME; MUTATION; NUCLEOTIDE SEQUENCE; TUMOR GENE;

ANIMALS; CARCINOMA, SQUAMOUS CELL; DNA MUTATIONAL ANALYSIS; GENES, NEOPLASM; GENOME, HUMAN; HEAD AND NECK NEOPLASMS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION;

EID: 84919617522     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12599     Document Type: Article

References (48)

1. Leemans, C.R., B.J. Braakhuis & R.H. Brakenhoff . 2011. The molecular biology of head and neck cancer. Nat. Reviews. Cancer 11: 9-22.
2. Jemal, A. et al. 2011. Global cancer statistics. Cancer J. Clin. 61: 69-90.
3. Haddad, R.I. & D.M. Shin . 2008. Recent advances in head and neck cancer. New Engl. J. Med. 359: 1143-1154.
4. Hennessey, P.T., W.H. Westra & J.A. Califano . 2009. Human papillomavirus and head and neck squamous cell carcinoma: recent evidence and clinical implications. J. Dental Res. 88: 300-306.
5. Agrawal, N. et al. 2011. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333: 1154-1157.
6. Stransky, N. et al. 2011. The mutational landscape of head and neck squamous cell carcinoma. Science 333: 1157-1160.
7. Nelson, N.J. 2013. Genetic events in head and neck squamous cell carcinoma revealed. J. Natl. Cancer Inst. 105: 1766-1768.
8. Pickering, C.R. et al. 2013. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 3: 770-781.
9. Gaykalova, D.A. et al. 2014. Novel insight into mutational landscape of head and neck squamous cell carcinoma. PloS One 9: e93102.
10. Tewhey, R. et al. 2009. Microdroplet-based PCR enrichment for large-scale targeted sequencing. Nat. Biotechnol. 27: 1025-1031.
11. Pickering, C.R. et al. 2014. Squamous cell carcinoma of the oral tongue in young non-smokers is genomically similar to tumors in older smokers. Clin. Cancer Res. 20: 3842-3848
12. Li, R. et al. 2014. Clinical, genomic and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head & Neck. doi: 10.1002/hed.23807.
13. Chaturvedi, A.K. et al. 2011. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin. Oncol. 29: 4294-4301.
14. - tumors. Genome Med. 5: 49.
15. Braakhuis, B. et al. 2013. TP53 mutation and human papilloma virus status of oral squamous cell carcinomas in young adult patients. Oral Dis 20: 602-608.
16. Nichols, A.C. et al. 2013. High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. JAMA Otolaryngol-Head Neck Surg. 139: 617-622.
17. Sewell, A. et al. 2014. Reverse-phase protein array profiling of oropharyngeal cancer and significance of PIK3CA mutations in HPV-associated head and neck cancer. Clin. Cancer Res. 20: 2300-2311.
18. Iglesias-Bartolome, R., D. Martin & J.S. Gutkind . 2013. Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets. Cancer Discov. 3: 722-725.
19. Brakenhoff, R.H. 2011. Cancer: another NOTCH for cancer. Science 333: 1102-1103.
20. Tassone, P. et al. 2013. p53-based therapeutics for head and neck squamous cell carcinoma. Oral Oncol. 49: 733-737.
21. Kandoth, C. et al. 2013. Mutational landscape and significance across 12 major cancer types. Nature 502: 333-339.
22. Powell, E., D. Piwnica-Worms & H. Piwnica-Worms . 2014. Contribution of p53 to metastasis. Cancer Discov. 4: 405-414.
23. Poeta, M.L. et al. 2007. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 357: 2552-2561.
24. Skinner, H.D. et al. 2012. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence. Clin. Cancer Res. 18: 290-300.
25. Cabelguenne, A. et al. 2000. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J. Clin. Oncol. 18: 1465-1473.
26. Perrone, F. et al. 2010. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. J. Clin. Oncol. 28: 761-766.
27. Mroz, E.A. & J.W. Rocco . 2010. Functional p53 status as a biomarker for chemotherapy response in oral-cavity cancer. J. Clin. Oncol. 28: 715-717.
28. Roh, J.L. et al. 2012. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett. 325: 35-41.
29. Yoo, G.H. et al. 2009. A phase 2 trial of surgery with perioperative INGN 201 (Ad5CMV-p53) gene therapy followed by chemoradiotherapy for advanced, resectable squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx: report of the Southwest Oncology Group. Arch. Otolaryngol.-Head Neck Surg. 135: 869-874.
30. Fishman, M.N. et al. 2011. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies. Clin. Cancer Res. 17: 7765-7775.
31. Courtney, K.D., R.B. Corcoran & J.A. Engelman . 2010. The PI3K pathway as drug target in human cancer. J. Clin. Oncol. 28: 1075-1083.
32. Lui, V.W. et al. 2013. Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers. Cancer Discov. 3: 761-769.
33. Li, H. et al. 2014. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection. Molec. Cancer Res. 12: 571-582.
34. Fury, M.G. et al. 2013. A phase 1 study of everolimus plus docetaxel plus cisplatin as induction chemotherapy for patients with locally and/or regionally advanced head and neck cancer. Cancer 119: 1823-1831.
35. Bauman, J.E. et al. 2013. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 49: 461-467.
36. Sethi, N. et al. 2011. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell. 19: 192-205.
37. Ntziachristos, P. et al. 2014. From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell. 25: 318-334.
38. Wang, N.J. et al. 2011. Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma. Proc. Natl. Acad. Sci. USA 108: 17761-17766.
39. Nicolas, M. et al. 2003. Notch1 functions as a tumor suppressor in mouse skin. Nat. Genet. 33: 416-421.
40. Proweller, A. et al. 2006. Impaired notch signaling promotes de novo squamous cell carcinoma formation. Cancer Res. 66: 7438-7444.
41. Puente, X.S. et al. 2011. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475: 101-105.
42. Weng, A.P. et al. 2004. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271.
43. Sun, W. et al. 2014. Activation of the NOTCH pathway in head and neck cancer. Cancer Res. 74: 1091-1104.
44. Song, X. et al. 2014. Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma. Clin. Cancer Res. 20: 701-710.
45. Krop, I. et al. 2012. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors. J. Clin. Oncol. 30: 2307-2313.
46. Tolcher, A.W. et al. 2012. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J. Clin. Oncol. 30: 2348-2353.
47. Parfenov, M. et al. 2014. Characterization of HPV and host genome interactions in primary head and neck cancers. Proc. Natl. Acad. Sci. USA. 111: 15544-15549.
48. Gross, A.M. et al. 2014. Multi-tiered genomic analysis of head and neck cancer ties TP53 mutation to 3p loss. Nat. Genet. 46: 939-943.